One specification note worth flagging: the COA returned for the blend reports the analytical results for each of the three component compounds separately
Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist that showed up to 24.2% weight loss in phase 2 trials at 48 weeks, potentially exceeding both CagriSema and tirzepatide
Low-bias phosphopeptide enrichment from scarce samples using plastic antibodies
(He notes that Amazon has since cleaned up injectables on its site, though oral BPC-157 is still available.) Turnock traces the rise of peptides, which can cost anywhere from a couple hundred to thousands per month depending on particular protocols, to a few big changes within the last decade
Third, mitochondrial support
Over 100 peer-reviewed studies have been published on BPC-157, the large majority in rodent models